Download PDF
Angewandte Nuklearmedizin 2025; 48(01): 15-23
DOI: 10.1055/a-2405-3314
Onkologie
Übersicht

Molekular zielgerichtete Therapien – brauchen wir überhaupt noch Chemotherapie?

Targeted therapies in the management of malignant lymphoma – is the end of conventional chemotherapy near?
Johannes C. Hellmuth
1   Medizinische Klinik und Poliklinik III, Klinikum der Universität München-Campus Grosshadern, München, Germany
,
Raphael Koch
2   Klinik für Hämatologie und Medizinische Onkologie, Georg-August-Universität, Universitätsmedizin Göttingen, Göttingen, Deutschland
,
Oliver Weigert
1   Medizinische Klinik und Poliklinik III, Klinikum der Universität München-Campus Grosshadern, München, Germany
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Zusammenfassung

Fortschritte im Verständnis der Biologie maligner Lymphome haben die Entwicklung zahlreicher molekular zielgerichteter Therapien ermöglicht. So kann die chronische lymphatische Leukämie heutzutage fast vollständig chemotherapiefrei behandelt werden. Doch wie sieht diese Entwicklung bei anderen Lymphomen aus? Im vorliegenden Artikel wollen wir eine Übersicht über molekular zielgerichtete Therapieansätze bei malignen B- und T-Zell-Lymphomen geben.

Abstract

Advances in the understanding of the biology of malignant lymphoma has facilitated the development of numerous molecularly targeted therapies. The incorporation of these precision therapeutics has produced more effective and often less-toxic treatment regimens leading to a significant improvement of treatment outcomes for individuals with lymphoid malignancies.

In relapsed diseases, molecularly targeted therapeutic approaches have demonstrated superior outcomes compared to conventional chemotherapy, leading to a growing number of patients being treated entirely chemotherapy-free. This review outlines the current landscape of targeted therapies for both B-cell (B-NHL) and T-cell non-Hodgkin lymphomas (T-NHL) and provides an overview of targeted agents currently approved for the treatment of malignant lymphoma.

Kernaussagen

  • Die Einführung molekular zielgerichteter Substanzen hat zu einer signifikanten Verbesserung der Therapieergebnisse für Patienten mit malignen Lymphomen geführt.

  • In der Erstlinie bleibt die Immunochemotherapie für die Mehrzahl der Patienten der Standard.

  • In der Rezidivsituation werden immer mehr Patienten vollständig chemotherapiefrei behandelt.

  • Ideale Kombinationspartner und Therapieabfolgen müssen für viele der neuen Substanzen in Studien erst noch definiert werden.

  • Bei T- und NK-Zell-Lymphomen besteht ein großer Forschungs- und Entwicklungsbedarf, um die bisher unbefriedigenden Therapieergebnisse für diese Patienten zu verbessern.

Schlüsselwörter

Therapie - zielgerichtet - Lymphome - Non-Hodgkin-Lymphom - Hodgkin-Lymphome

Keywords

therapy - targeted - lymphoma - Non-Hodgkin-lymphoma - Hodgkin-lymphoma


Publication History

Article published online:
26 February 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Alig S, Pott C, Chapuy B. Maligne Lymphome – Quo vadis?. Dtsch Med Wochenschr 2024; 149: 638-645
    CrossrefPubMedSearch in Google Scholar
  • 2 Minson A, Tam C, Dickinson M. et al. Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas. Cancers (Basel) 2022; 14: 1276
    CrossrefPubMedSearch in Google Scholar
  • 3 Gill S, Vides V, Frey NV. et al. Anti-CD19 CAR T cells in combination with ibrutinib for the treatment of chronic lymphocytic leukemia. Blood Adv 2022; 6: 5774-5785
    CrossrefPubMedSearch in Google Scholar
  • 4 Tam CS, Opat S, D’Sa S. et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood 2020; 136: 2038-2050
    CrossrefPubMedSearch in Google Scholar
  • 5 Byrd JC, Hillmen P, Ghia P. et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol 2021; 39: 3441-3452
    CrossrefPubMedSearch in Google Scholar
  • 6 Fruman DA, Chiu H, Hopkins BD. et al. The PI3K Pathway in Human Disease. Cell 2017; 170: 605-635
    CrossrefPubMedSearch in Google Scholar
  • 7 Xu W, Berning P, Lenz G. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood 2021; 138: 1110-1119
    CrossrefPubMedSearch in Google Scholar
  • 8 Johnston PB, Pinter-Brown LC, Warsi G. et al. Phase 2 study of everolimus for relapsed or refractory classical Hodgkin lymphoma. Exp Hematol Oncol 2018; 7: 12
    CrossrefPubMedSearch in Google Scholar
  • 9 Rule S, Jurczak W, Jerkeman M. et al. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. Leukemia 2018; 32: 1799-1803
    CrossrefPubMedSearch in Google Scholar
  • 10 Hess G, Herbrecht R, Romaguera J. et al. Phase III Study to Evaluate Temsirolimus Compared With Investigator’s Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma. JCO 2009; 27: 3822-3829
    CrossrefPubMedSearch in Google Scholar
  • 11 Wang M. Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study. ASH. 2023 Accessed March 10, 2024 at: https://ash.confex.com/ash/2023/webprogram/Paper191921.html
    Search in Google Scholar
  • 12 Robak T, Jin J, Pylypenko H. et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. The Lancet Oncology 2018; 19: 1449-1458
    CrossrefPubMedSearch in Google Scholar
  • 13 Fink EC, Ebert BL. The novel mechanism of lenalidomide activity. Blood 2015; 126: 2366-2369
    CrossrefPubMedSearch in Google Scholar
  • 14 Morschhauser F, Fowler NH, Feugier P. et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med 2018; 379: 934-947
    CrossrefPubMedSearch in Google Scholar
  • 15 Morin RD, Mendez-Lago M, Mungall AJ. et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303
    CrossrefPubMedSearch in Google Scholar
  • 16 Pastore A, Jurinovic V, Kridel R. et al. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. The Lancet Oncology 2015; 16: 1111-1122
    CrossrefPubMedSearch in Google Scholar
  • 17 Béguelin W, Popovic R, Teater M. et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013; 23: 677-692
    CrossrefPubMedSearch in Google Scholar
  • 18 Morschhauser F, Tilly H, Chaidos A. et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial. Lancet Oncol 2020; 21: 1433-1442
    CrossrefPubMedSearch in Google Scholar
  • 19 Nachmias B, Schimmer AD. Targeting nuclear import and export in hematological malignancies. Leukemia 2020; 34: 2875-2886
    CrossrefPubMedSearch in Google Scholar
  • 20 Kalakonda N, Maerevoet M, Cavallo F. et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial. Lancet Haematol 2020; 7: e511-e522
    CrossrefPubMedSearch in Google Scholar
  • 21 Marcus R, Davies A, Ando K. et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. New England Journal of Medicine 2017; 377: 1331-1344
    CrossrefPubMedSearch in Google Scholar
  • 22 Herrera AF, LeBlanc ML, Castellino SM. et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL). JCO 2023; 41: LBA4-LBA4
    CrossrefSearch in Google Scholar
  • 23 Cheson BD, Bartlett NL, LaPlant B. et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial. Lancet Haematol 2020; 7: e808-e815
    CrossrefPubMedSearch in Google Scholar
  • 24 Hartmann S, Rudelius M. Neue Klassifikationen maligner Lymphome – Welche Änderungen sind für die Praxis relevant?. Dtsch Med Wochenschr 2024; 149: 613-620
    Thieme ConnectPubMedSearch in Google Scholar
  • 25 Stuver R, Moskowitz AJ. Therapeutic Advances in Relapsed and Refractory Peripheral T-Cell Lymphoma. Cancers (Basel) 2023; 15: 589
    CrossrefPubMedSearch in Google Scholar
  • 26 Mehta-Shah N, Jacobsen E, Luigi Zinzani P. et al. P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY. Hemasphere 2023; 7: e3891642
    CrossrefSearch in Google Scholar
  • 27 Ruan J, Moskowitz A, Mehta-Shah N. et al. Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood 2023; 141: 2194-2205
    CrossrefPubMedSearch in Google Scholar